Jim Simons
VIR icon

Jim Simons’s Vir Biotechnology VIR Stock Holding History

Jim Simons’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
1,016,864
+255,500
+34% +$2.43M 0.01% 1040
2026
Q1 		$6.82M Buy
761,364
+146,900
+24% +$1.17M 0.01% 1182
2025
Q4 		$3.71M Sell
614,464
-552,636
-47% -$3.29M 0.01% 1498
2025
Q3 		$6.66M Buy
1,167,100
+102,600
+10% +$525K 0.01% 1318
2025
Q2 		$5.37M Sell
1,064,500
-55,900
-5% -$300K 0.01% 1478
2025
Q1 		$7.26M Sell
1,120,400
-117,200
-9% -$1.04M 0.01% 1194
2024
Q4 		$9.08M Buy
1,237,600
+55,300
+5% +$436K 0.01% 1077
2024
Q3 		$8.86M Sell
1,182,300
-147,400
-11% -$1.28M 0.01% 1103
2024
Q2 		$11.8M Sell
1,329,700
-26,400
-2% -$253K 0.02% 828
2024
Q1 		$13.7M Buy
1,356,100
+61,500
+5% +$626K 0.02% 827
2023
Q4 		$13M Sell
1,294,600
-59,800
-4% -$546K 0.02% 817
2023
Q3 		$12.7M Buy
1,354,400
+186,300
+16% +$2.66M 0.02% 785
2023
Q2 		$28.7M Buy
1,168,100
+7,600
+0.7% +$191K 0.04% 509
2023
Q1 		$27M Buy
1,160,500
+102,100
+10% +$2.61M 0.04% 576
2022
Q4 		$26.8M Sell
1,058,400
-454,094
-30% -$11.1M 0.04% 582
2022
Q3 		$29.2M Buy
1,512,494
+950,094
+169% +$24.2M 0.04% 500
2022
Q2 		$14.3M Buy
562,400
+468,000
+496% +$10.9M 0.02% 911
2022
Q1 		$2.43M Buy
94,400
+36,500
+63% +$1.08M ﹤0.01% 2083
2021
Q4 		$2.42M Buy
+57,900
New +$2.27M ﹤0.01% 1985
2021
Q3 		– Sell
-80,102
Closed -$3.79M – 3869
2021
Q2 		$3.79M Buy
+80,102
New +$3.64M ﹤0.01% 1806
2020
Q2 		– Sell
-58,500
Closed -$2M – 3793
2020
Q1 		$2M Buy
+58,500
New +$1.57M ﹤0.01% 2046

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SB Investment Advisers (UK)
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GSK plc
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Jim Simons's VIR Position: Q2 2026 in Review

Jim Simons increased its Vir Biotechnology (VIR) stake by 34% in Q2 2026, buying an estimated $2.43M and bringing the position to 1,016,864 shares worth $10.4M. The position accounts for 0.01% of the portfolio, ranked #1040.

Jim Simons first reported a position in VIR in Q1 2020 and has held it in 21 quarters since. The position peaked at $29.2M in Q3 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Jim Simons held 1,016,864 shares of Vir Biotechnology worth $10.4M as of Q2 2026.
  • Jim Simons bought 255,500 Vir Biotechnology shares in Q2 2026, an estimated $2.43M.
  • Vir Biotechnology made up 0.01% of Jim Simons's portfolio in Q2 2026, its #1040 holding.
  • Jim Simons first reported a position in Vir Biotechnology in Q1 2020 and has held it in 21 quarters since.
  • Jim Simons's Vir Biotechnology position peaked at $29.2M in Q3 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.